258 related articles for article (PubMed ID: 21934531)
1. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
2. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
3. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
[TBL] [Abstract][Full Text] [Related]
4. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
[TBL] [Abstract][Full Text] [Related]
5. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Krikov M; Thone-Reineke C; Müller S; Villringer A; Unger T
J Hypertens; 2008 Mar; 26(3):544-52. PubMed ID: 18300867
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia.
Hosomi N; Nishiyama A; Ban CR; Naya T; Takahashi T; Kohno M; Koziol JA
Neuroscience; 2005; 134(1):225-31. PubMed ID: 15963646
[TBL] [Abstract][Full Text] [Related]
7. Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Panahpour H; Nekooeian AA; Dehghani GA
Iran Biomed J; 2014; 18(4):232-8. PubMed ID: 25326022
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.
Elewa HF; Kozak A; Johnson MH; Ergul A; Fagan SC
J Hypertens; 2007 Apr; 25(4):855-9. PubMed ID: 17351379
[TBL] [Abstract][Full Text] [Related]
11. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
12. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Fagan SC; Kozak A; Hill WD; Pollock DM; Xu L; Johnson MH; Ergul A; Hess DC
J Hypertens; 2006 Mar; 24(3):535-9. PubMed ID: 16467657
[TBL] [Abstract][Full Text] [Related]
13. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
[TBL] [Abstract][Full Text] [Related]
14. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
Lange SA; Wolf B; Schober K; Wunderlich C; Marquetant R; Weinbrenner C; Strasser RH
J Cardiovasc Pharmacol; 2007 Jan; 49(1):46-55. PubMed ID: 17261963
[TBL] [Abstract][Full Text] [Related]
15. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Singh N; Sharma G; Singh N; Hanif K
Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
[TBL] [Abstract][Full Text] [Related]
18. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
Hamai M; Iwai M; Ide A; Tomochika H; Tomono Y; Mogi M; Horiuchi M
Neuropharmacology; 2006 Sep; 51(4):822-8. PubMed ID: 16824557
[TBL] [Abstract][Full Text] [Related]
19. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T
Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
